Physician profile
George M Markus
NPI 1295831535
$2,323.07
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $368 · 2021: $244 · 2022: $722 · 2023: $653 · 2024: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $537.43 | 2022-2024 | Gallant |
| Novo Nordisk INC | $414.21 | 2019-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $373.52 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $224.39 | 2019-2023 | Breztri |
| Otsuka America Pharmaceutical, INC. | $199.86 | 2022-2023 | Rexulti |
| Astellas Pharma US INC | $99.99 | 2022 | |
| Sanofi-Aventis U.S. LLC | $70.92 | 2020-2021 | |
| Pfizer INC. | $70.83 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.31 | 2020-2021 | |
| Lilly USA, LLC | $65.88 | 2020-2021 | |
| Glaxosmithkline, LLC. | $55.61 | 2020 | |
| Janssen Pharmaceuticals, INC | $51.23 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $29.60 | 2019 | |
| Sumitomo Pharma America, INC. | $17.71 | 2023 | Gemtesa |
| Merck Sharp & Dohme LLC | $16.99 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.94 | 2019 | |
| Allergan, INC. | $11.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Markus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.